Researchers at the Montreal Heart Institute launched a global study titled COLCOT (COLchicine Cardiovascular Outcomes Trial) in 2014. The goal was to determine whether colchicine, a widely available drug, could prevent the risk of heart attacks in patients who had already experienced this kind of event.
Colchicine is an orally administered drug which has been garnering a lot of interest in the past few months. It has recently been the subject of scientific studies that have identified new indications. Let’s take a look at this readily available drug that represents a new hope for people with a variety of health conditions.
The Colcorona genetic study is taking place at the Montreal Heart Institute’s Beaulieu-Saucier Pharmacogenomics Centre and is led by Dr. Marie-Pierre Dubé. This study invited participants who have already accepted to take part in the Colcorona study to voluntarily contribute their DNA. The study of their DNA will help researchers better understand why some patients develop a more severe form of COVID-19.
Through the acquisition of the da Vinci Xi surgical robot, the Montreal Heart Institute became the first medical establishment in Canada to devote this type of technology exclusively to cardiac surgery. An object of fascination and curiosity, the robot allows the Institute to work with next-level techniques and maintain its position as a leader in the field of precision medicine.